Structure-Activity Relationships of Dopamine Transporter Pharmacological Chaperones
Authors:
Open Access
- 9 May 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 16, 832536
Abstract
Mutations in the dopamine transporter gene (SLC6A3) have been implicated in many human diseases. Among these is the infantile parkinsonism-dystonia known as Dopamine Transporter Deficiency Syndrome (DTDS). Afflicted individuals have minimal to no functional dopamine transporter protein. This is primarily due to retention of misfolded disease-causing dopamine transporter variants. This results in a variety of severe motor symptoms in patients and the disease ultimately leads to death in adolescence or young adulthood. Though no treatment is currently available, pharmacological chaperones targeting the dopamine transporter have been shown to rescue select DTDS disease-causing variants. Previous work has identified two DAT pharmacological chaperones with moderate potency and efficacy: bupropion and ibogaine. In this study, we carried out structure-activity relationships (SARs) for bupropion and ibogaine with the goal of identifying the chemical features required for pharmacological chaperone activity. Our results show that the isoquinuclidine substituent of ibogaine and its analogs is an important feature for pharmacological chaperone efficacy. For bupropion, the secondary amine group is essential for pharmacological chaperone activity. Lastly, we describe additional ibogaine and bupropion analogs with varying chemical modifications and variable pharmacological chaperone efficacies at the dopamine transporter. Our results contribute to the design and refinement of future dopamine transporter pharmacological chaperones with improved efficacies and potencies.Keywords
Funding Information
- Canadian Institutes of Health Research
- National Institutes of Health
- Natural Sciences and Engineering Research Council of Canada
- National Institutes of Health
This publication has 42 references indexed in Scilit:
- Nonclassical Pharmacology of the Dopamine Transporter: Atypical Inhibitors, Allosteric Modulators, and Partial SubstratesThe Journal of Pharmacology and Experimental Therapeutics, 2013
- The Mechanistic Basis for Noncompetitive Ibogaine Inhibition of Serotonin and Dopamine TransportersJournal of Biological Chemistry, 2012
- Synthesis of 2-(Substituted Phenyl)-3,5,5-trimethylmorpholine Analogues and Their Effects on Monoamine Uptake, Nicotinic Acetylcholine Receptor Function, and Behavioral Effects of NicotineJournal of Medicinal Chemistry, 2011
- Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental studyThe Lancet Neurology, 2011
- Synthesis and Characterization of in Vitro and in Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking CessationJournal of Medicinal Chemistry, 2010
- Synthesis and Biological Evaluation of Bupropion Analogues as Potential Pharmacotherapies for Smoking CessationJournal of Medicinal Chemistry, 2010
- Functional Rescue of β1‐Adrenoceptor Dimerization and Trafficking by Pharmacological ChaperonesTraffic, 2009
- Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystoniaJournal of Clinical Investigation, 2009
- Anomalous Dopamine Release Associated with a Human Dopamine Transporter Coding VariantJournal of Neuroscience, 2008
- Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic PainThe Journal of Pharmacology and Experimental Therapeutics, 2007